This is a Phase II study seeking to determine whether administration of different doses of glutathione or placebo, as a nasal spray, improves Parkinson’s disease (PD) symptoms over time in a population of individuals with PD. Participants will be asked to administer the nasal spray or placebo three times daily for three months.
Individuals must have been diagnosed with Parkinson's disease in the past 10 years, must not currently be using glutathione in any form, and must be able to come to Bastyr for five visits over four months. Study medication will be provided and participants will be reimbursed for transportation costs.
The recruitment phase is complete. We are no longer recruiting participants for this trial.
Excessive free radical formation and depletion of the brain’s primary antioxidant, glutathione, are established components of Parkinson’s disease (PD) pathophysiology. While there is rationale for the therapeutic use of reduced glutathione (GSH) in PD, and even some preliminary evidence to suggest the use of GSH can lead to symptomatic improvement, obstacles surrounding currently employed delivery methods have hindered the clinical utility of this therapy. Intranasal GSH is a novel method of delivery in patients with PD, and bypasses the obstacles associated with other delivery methods. It has been used in clinical practice since 2005. The aim of this study is to evaluate whether administration of different doses of glutathione or placebo, as a nasal spray, improves Parkinson’s disease (PD) symptoms over time in a population of individuals with PD.